Chronic Leukemia

被引：2

作者：

Greenberg, Edythe M. ^{[1
]}

Probst, Alexandra ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

CRITICAL CARE NURSING CLINICS OF NORTH AMERICA | 2013年 / 25卷 / 04期

关键词：

Chronic myeloid leukemia; Chronic lymphocytic leukemia; Leukocytosis; Lymphocytosis; Tyrosine kinase inhibitors; Alkylating agents; Monoclonal antibodies; Immunomodulatory; DIAGNOSED CHRONIC-PHASE; CHRONIC MYELOID-LEUKEMIA; INITIAL THERAPY; FOLLOW-UP; IMATINIB; CYCLOPHOSPHAMIDE; COMBINATION; FLUDARABINE; DASATINIB; NILOTINIB;

D O I：

10.1016/j.ccell.2013.09.003

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

The chronic leukemias include chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). CML is a clonal myeloproliferative hematopoietic stem-cell disorder, and CLL is a monoclonal B-cell disorder. CML is Philadelphia chromosome positive. There are 3 phases of CML: the chronic phase, the accelerated phase, and the blast phase. The primary treatment of CML consists of tyrosine kinase inhibitors. CLL can present as indolent or fulminant disease. Early disease is managed with observation. Fulminant disease is currently treated with alkylating agents, purine analogues, and monoclonal antibodies, but new biotarged therapies are being developed.

引用

页码：459 / +

页数：13

共 34 条

[1]

Baccarani M, 2009, BLOOD ASH ANNUAL MEE, P114

[2] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[3] Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia [J].

Badoux, Xavier C. ;

Keating, Michael J. ;

Wen, Sijin ;

Lee, Bang-Ning ;

Sivina, Mariela ;

Reuben, James ;

Wierda, William G. ;

O'Brien, Susan M. ;

Faderl, Stefan ;

Kornblau, Steven M. ;

Burger, Jan A. ;

Ferrajoli, Alessandra .

BLOOD, 2011, 118 (13) :3489-3498

[4]

Beutler E, 2010, WILLIAMS HEMATOLOGY, P777

[5] Immunomodulatory Drugs and Active Immunotherapy for Chronic Lymphocytic Leukemia [J].

Carballido, Estrella ;

Veliz, Marays ;

Komrokji, Rami ;

Pinilla-Ibarz, Javier .

CANCER CONTROL, 2012, 19 (01) :54-67

[6]

Cortes J, 2011, CHRONIC MYELOID LEUK

[7] How I treat newly diagnosed chronic phase CML [J].

Cortes, Jorge ;

Kantarjian, Hagop .

BLOOD, 2012, 120 (07) :1390-1397

[8] Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias [J].

Cortes, Jorge E. ;

Kantarjian, Hagop ;

Shah, Neil P. ;

Bixby, Dale ;

Mauro, Michael J. ;

Flinn, Ian ;

O'Hare, Thomas ;

Hu, Simin ;

Narasimhan, Narayana I. ;

Rivera, Victor M. ;

Clackson, Tim ;

Turner, Christopher D. ;

Haluska, Frank G. ;

Druker, Brian J. ;

Deininger, Michael W. N. ;

Talpaz, Moshe .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (22) :2075-2088

[9] Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial [J].

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Kantarjian, Hagop M. ;

Bruemmendorf, Tim H. ;

Dyagil, Irina ;

Griskevicius, Laimonas ;

Malhotra, Hemant ;

Powell, Christine ;

Gogat, Karin ;

Countouriotis, Athena M. ;

Gambacorti-Passerini, Carlo .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3486-3492

[10]

Dearden Claire, 2008, Hematology Am Soc Hematol Educ Program, P450, DOI 10.1182/asheducation-2008.1.450

← 1 2 3 4 →